Clinical Research Directory
Browse clinical research sites, groups, and studies.
NO Re-excision MelanomA - NORMA 2
Sponsor: Marieke Goodijk
Summary
This multicenter, phase III randomized controlled trial evaluates whether omitting re-excision after complete primary excision of cutaneous melanoma affects patient outcomes. A total of 1,749 patients with pT1b-pT4b cutaneous melanoma without evidence of metastases will be randomized to either standard re-excision according to current guidelines or no re-excision. Sentinel lymph node biopsy and adjuvant systemic therapy will be performed as indicated in both groups. The primary objective is to compare relapse-free survival (RFS) between the two groups. Secondary objectives include comparisons of overall survival (OS), local recurrence rates, recurrence of in-transit and lymph node metastases, distant metastasis-free survival (DMFS), surgical morbidity, quality of life, and health economic outcomes.
Official title: Multicenter Phase 3 Randomized Controlled Trial of NO Re-excision MelanomA - NORMA 2
Key Details
Gender
All
Age Range
Any - Any
Study Type
INTERVENTIONAL
Enrollment
1749
Start Date
2025-11-13
Completion Date
2033-11
Last Updated
2026-04-15
Healthy Volunteers
No
Conditions
Interventions
Re-excision
Prior to the re-excision, before any local anesthetic is given, the margin will be measured by a ruler and marked on the skin of the patient. The melanoma free margin of the diagnostic excision may be subtracted from the re-excision margin. The re-excision should be performed by cutting vertically down along the margins of the re-excision for its entire length until the required margin or until the fascia is reached in the depth. Removal of the fascia is left to the resecting surgeon's discretion. Preservation of anatomical structures, such as veins or nerves is allowed, if they are not clearly involved with tumor. In case of melanoma ≥pT3a any margin between 1 and 2 centimeter is accepted according to the surgeons preference. The amount of margin (in mm) taken during the re-excision needs to be documented perioperatively by the surgeon in the operation report. The specimen should be marked for anatomical navigation and sent off for pathological assessment.
No re-excision
In case a patient is randomized toward the no-re-excision treatment arm, there is no need to perform any procedures to the primary tumor site.
Locations (21)
Jeroen Bosch Ziekenhuis
's-Hertogenbosch, Netherlands
Noordwest Ziekenhuisgroep
Alkmaar, Netherlands
Flevoziekenhuis
Almere Stad, Netherlands
Antoni van Leeuwenhoek
Amsterdam, Netherlands
Gelre ziekenhuizen
Apeldoorn, Netherlands
Rijnstate Ziekenhuis
Arnhem, Netherlands
Catharina ziekenhuis
Eindhoven, Netherlands
Medisch Spectrum Twente
Enschede, Netherlands
Groene Hart Ziekenhuis
Gouda, Netherlands
Martini ziekenhuis
Groningen, Netherlands
Tergooi MC
Hilversum, Netherlands
Dijklander Ziekenhuis
Hoorn, Netherlands
Alrijne Ziekenhuis
Leiden, Netherlands
Leids Universitair Medisch Centrum
Leiden, Netherlands
Maastricht UMC
Maastricht, Netherlands
Maasstad Ziekenhuis
Rotterdam, Netherlands
Haaglanden Medisch Centrum
The Hague, Netherlands
Haga Ziekenhuis
The Hague, Netherlands
Diakonessenhuis
Utrecht, Netherlands
St. Antonius Ziekenhuis
Utrecht, Netherlands
Isala Ziekenhuis
Zwolle, Netherlands